Skip to main content
Jonathan Schatz, MD, Oncology, Miami, FL, University of Miami Hospital

JonathanHarrySchatzMD

Oncology Miami, FL

Hematologic Oncology

Associate Professor, Medicine, University of Miami Miller School of Medicine

Dr. Schatz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Schatz's full profile

Already have an account?

Summary

  • Dr. Jonathan Schatz is a physician-scientist in Miami, FL at University of Miami Hospital and University of Miami Hospital and Clinics. He received his medical degree from University of Chicago Division of the Biological Sciences The Pritzker School of Medicine and has been in practice 13 years. He trained in hematology-oncology at Memorial Sloan-Kettering Cancer Center. He specializes in hematologic oncology and is experienced in Hodgkin and non-Hodgkin lymphomas. He has more than 50 publications and over 2,500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 2004 - 2007
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2004

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2015 - 2025
  • AZ State Medical License
    AZ State Medical License 2012 - 2015
  • NY State Medical License
    NY State Medical License 2007 - 2012
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Mortimer J. Lacher Fellowship Memorial Sloan-Kettering Cancer Center, 2009
  • First Place, Resident Poster Competition American College of Physicians, Northern Illinois Chapter Scientific Meeting, 2005
  • Leon O. Jacobson Prize University of Chicago Pritzker School of Medicine, 2004
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells  
    Amin AD, Rajan SS, Groysman MJ, Pongtornpipat P, Schatz JH, Biomarkers in Cancer, 1/15/2015
  • Kinase overexpressing cancers responsive to drug withdrawal  
    Amin AD, Rajan SS, Schatz JH, Aging, 1/1/2015
  • Evidence suggesting that discontinuous dosing of ALK kinase inhibitors may prolong control of ALK+ tumors  
    Amin AD, Rajan SS, Lang WS, Pongtornpipat P, Groysman MJ, Tapia EO, Tula-Sanchez AA, Peters TL, Cuyugan L, Adkins J, Rimsza LM, Lussier YA, Puvvada SD, Schatz JH, Cancer Research, 1/1/2015
  • Join now to see all

Abstracts/Posters

  • Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
    Jonathan H. Schatz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint R...
    Jonathan H. Schatz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics
    Jonathan H. Schatz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Discovery and Early Characterization of a New Inhibitor of Cap-Dependent Translation for Cancer Therapy. 
    University of Miami - 1/1/2016
  • The China Lymphoma Project: A Medical Perspective. 
    1/1/2016
  • Studies of Preclinical Therapeutics and Resistance in Lymphoma Model Systems. 
    University of Arizona - 1/1/2015
  • Join now to see all

Press Mentions

  • Castaways Against Cancer Announces Five-Year Commitment to Sylvester Comprehensive Cancer Center
    Castaways Against Cancer Announces Five-Year Commitment to Sylvester Comprehensive Cancer CenterMarch 15th, 2022
  • Bispecific Antibodies Treat Cancer in Mouse Models
    Bispecific Antibodies Treat Cancer in Mouse ModelsMarch 5th, 2021

Hospital Affiliations